ERBB2 and non-small cell lung carcinoma: These different phases were originally demonstrated for EGFR-targeted therapies in non-small cell lung cancer (NSCLC) cells (Sharma et al, 2010), but the concept has been expanded more recently to other malignancies including HER2+ breast cancer (Chang et al, 2022; De Conti et al, 2021; Dhimolea et al, 2021; Hata et al, 2016; Kurppa et al, 2020; Sharma et al, 2010).